Literature DB >> 11226744

Effects of melatonin in perimenopausal and menopausal women: a randomized and placebo controlled study.

G Bellipanni1, P Bianchi, W Pierpaoli, D Bulian, E Ilyia.   

Abstract

In aging humans, night levels of melatonin (MEL) decline progressively. Also thyroid and gonadal functions decline during aging while gonadotropins (luteotropic hormone (LH) and follicle stimulating hormone (FSH)) steadily increase. A desynchronization of pineal circadian cyclicity as expressed by the progressive decrease of the MEL night peak may be permissively linked to the onset and progression of menopause. We studied the effects of exogenous, evening administration of MEL on the level of hormones which are known to be involved in the genesis and progression of menopause. Perimenopausal and menopausal women from 42 to 62years of age with no pathology or medication were selected. MEL was measured in saliva to divide them into low, medium and high-MEL patients. Half of them took 3mg MEL and half of them Placebo at bedtime (10-12p.m.) in a fully randomized and double-blind fashion. Three and six months later blood was taken for determination of pituitary (LH, FSH), ovarian, and thyroid hormones I(T3 and T4). All women taking MEL with low basal level of MEL and/or Placebo for three and six months showed a significant increase in levels of thyroid hormones. Before initiation of the study, a negative correlation was found in all women between LH, FSH and basal MEL levels. Within six months of treatment, MEL produced a significant diminution of LH in the younger women (43 to 49year-old), while no effect was seen in the older women (50-62years old). A decrement of FSH was observed in MEL-treated women with low basal MEL levels. In addition, most MEL-treated women reported a general improvement of mood and a significant mitigation of depression. MEL decline during aging may thus signal the derangement of pineal and pituitary-controlled ovarian cyclicity and the progressive quenching of fertility in women. These findings seem to show a recovery of pituitary and thyroid functions in MEL-treated women, towards a more juvenile pattern of regulation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11226744     DOI: 10.1016/s0531-5565(00)00217-5

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN: 0531-5565            Impact factor:   4.032


  28 in total

Review 1.  The therapeutic potential of melatonin: a review of the science.

Authors:  Samir Malhotra; Girish Sawhney; Promila Pandhi
Journal:  MedGenMed       Date:  2004-04-13

2.  A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes.

Authors:  Wendy Y Chen; Anita Giobbie-Hurder; Kathryn Gantman; Jennifer Savoie; Rochelle Scheib; Leroy M Parker; Eva S Schernhammer
Journal:  Breast Cancer Res Treat       Date:  2014-04-10       Impact factor: 4.872

Review 3.  Adverse Events Associated with Melatonin for the Treatment of Primary or Secondary Sleep Disorders: A Systematic Review.

Authors:  Frank M C Besag; Michael J Vasey; Kim S J Lao; Ian C K Wong
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

Review 4.  Transplantation of human umbilical cord mesenchymal stem cells to treat premature ovarian failure.

Authors:  Oldouz Shareghi-Oskoue; Leili Aghebati-Maleki; Mehdi Yousefi
Journal:  Stem Cell Res Ther       Date:  2021-08-11       Impact factor: 8.079

Review 5.  Complementary and alternative medicine for sleep disturbances in older adults.

Authors:  Nalaka S Gooneratne
Journal:  Clin Geriatr Med       Date:  2008-02       Impact factor: 3.076

Review 6.  Melatonin for the treatment of irritable bowel syndrome.

Authors:  Kewin Tien Ho Siah; Reuben Kong Min Wong; Khek Yu Ho
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

7.  Sex hormones, sleep, and core body temperature in older postmenopausal women.

Authors:  Patricia J Murphy; Scott S Campbell
Journal:  Sleep       Date:  2007-12       Impact factor: 5.849

8.  Sleep, Melatonin, and the Menopausal Transition: What Are the Links?

Authors:  Shazia Jehan; Giardin Jean-Louis; Ferdinand Zizi; Evan Auguste; Seitikurippu R Pandi-Perumal; Ravi Gupta; Hrayr Attarian; Samy I McFarlane; Rüdiger Hardeland; Amnon Brzezinski
Journal:  Sleep Sci       Date:  2017 Jan-Mar

9.  Melatonin delays ovarian aging in mice by slowing down the exhaustion of ovarian reserve.

Authors:  Chan Yang; Qinghua Liu; Yingjun Chen; Xiaodong Wang; Zaohong Ran; Fang Fang; Jiajun Xiong; Guoshi Liu; Xiang Li; Liguo Yang; Changjiu He
Journal:  Commun Biol       Date:  2021-05-06

10.  Agomelatine, A Potential Multi-Target Treatment Alternative for Insomnia, Depression, and Osteoporosis in Postmenopausal Women: A Hypothetical Model.

Authors:  Ahmet Yardimci; Mehmet Ridvan Ozdede; Haluk Kelestimur
Journal:  Front Psychiatry       Date:  2021-06-29       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.